Peter U. Feig, MD; Gale H. Rutan, MD, MPH
More than 30 000 persons annually develop end-stage renal disease as a result of inexorably progressive renal insufficiency. Because of successful development and funding of maintenance therapy, over 120 000 patients live either on chronic dialysis or with renal allografts. The program has high morbidity and costs about $3 billion per year, that is, approximately $25 000 per patient. Further successes in prolonging life on maintenance therapy without affecting the rate of development of renal failure will result in further increases in this number, with the fastest growth among persons over age 65 (1). Arresting the progression of renal deterioration
Learn more about subscription options.
Register Now for a free account.
Feig PU, Rutan GH. Angiotensin Converting Enzyme Inhibitors: The End of End-Stage Renal Disease?. Ann Intern Med. 1989;111:451–453. doi: 10.7326/0003-4819-111-6-451
Download citation file:
Published: Ann Intern Med. 1989;111(6):451-453.
Cardiology, Chronic Kidney Disease, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only